308 related articles for article (PubMed ID: 16127030)
1. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
3. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
[TBL] [Abstract][Full Text] [Related]
4. [In vitro activity of caspofungin against fluconazole-resistant Candida isolates from patients with HIV infection].
Ortiz de la Tabla-Ducasse V; Masiá-Canuto M; Martín-González C; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2004; 22(6):328-31. PubMed ID: 15228899
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
6. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
[TBL] [Abstract][Full Text] [Related]
7. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
8. Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.
Cantón E; Pemán J; Gobernado M; Alvarez E; Baquero F; Cisterna R; Gil J; Martín-Mazuelos E; Rubio C; Sánchez-Sousa A; Serrano C
Antimicrob Agents Chemother; 2005 Apr; 49(4):1604-7. PubMed ID: 15793151
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry susceptibility testing for the antifungal caspofungin.
Mitchell M; Hudspeth M; Wright A
J Clin Microbiol; 2005 Jun; 43(6):2586-9. PubMed ID: 15956368
[TBL] [Abstract][Full Text] [Related]
10. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
Peter J; Armstrong D; Lyman CA; Walsh TJ
J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology and clinical use of caspofungin.
Hope WW; Shoham S; Walsh TJ
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):263-74. PubMed ID: 17428155
[TBL] [Abstract][Full Text] [Related]
12. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Hakki M; Staab JF; Marr KA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
[TBL] [Abstract][Full Text] [Related]
13. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2004 Jul; 42(7):3117-9. PubMed ID: 15243069
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Kartsonis N; DiNubile MJ; Bartizal K; Hicks PS; Ryan D; Sable CA
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):183-7. PubMed ID: 12394797
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Pfaller MA; Diekema DJ; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2003 Mar; 47(3):1068-71. PubMed ID: 12604543
[TBL] [Abstract][Full Text] [Related]
17. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
Cota J; Carden M; Graybill JR; Najvar LK; Burgess DS; Wiederhold NP
Antimicrob Agents Chemother; 2006 Nov; 50(11):3926-8. PubMed ID: 16940061
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration.
Majoros L; Kardos G; Szabó B; Sipiczki M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3486-8. PubMed ID: 16048965
[TBL] [Abstract][Full Text] [Related]
20. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
